Introduction
In a landmark move, UnitedHealthcare has approved reimbursement for the PoNS® (Portable Neuromodulation Stimulator) device used in treating gait and balance issues in patients with Multiple Sclerosis (MS). This decision is a major step forward in making advanced neuromodulation therapy accessible and affordable for more individuals across the United States.
What is the PoNS Device?
The PoNS device is a non-invasive neuromodulation therapy designed to improve walking and balance in people with MS. It works by delivering mild electrical pulses to the tongue, stimulating the brain to enhance movement coordination. The device is used along with a guided physical therapy program, amplifying its effectiveness.
Why This Approval Matters
Until now, access to the PoNS device was limited due to high out-of-pocket costs. UnitedHealthcare’s recent decision makes them the second major U.S. insurer—after Anthem—to cover this advanced treatment. This means thousands of MS patients may now afford the therapy that was once financially out of reach.
Reimbursement Coverage Details
-
Total Covered Amount: $18,100 (including patient co-pay)
-
Eligibility: Patients diagnosed with MS, experiencing gait deficits, and aged 22 or older
-
Coverage Status: Out-of-network reimbursement approved
This approval reflects the growing confidence in the clinical value of the PoNS device and its potential to transform MS therapy.
Benefits for Patients with MS
-
Improved walking and balance
-
Non-invasive and drug-free therapy
-
More affordable access through insurance
-
Can be used at home with physical therapy supervision
What This Means for the Market
Helius Medical Technologies, the company behind PoNS, is now closer to gaining wider commercial insurance coverage. This could potentially lead to:
-
Greater adoption of neuromodulation devices
-
Increased awareness about non-drug therapies for MS
-
More investment in neurorehabilitation technology
Final Thoughts
The UnitedHealthcare reimbursement approval is a significant breakthrough for the MS community. It not only expands access to a promising therapy but also signals a shift in how insurance companies are recognizing innovative, non-invasive treatments. As healthcare continues to evolve, such moves are critical in improving quality of life for chronic disease patients.
Tags: UnitedHealthcare MS Device Coverage, PoNS Device Reimbursement, Multiple Sclerosis Treatment 2025, Neuromodulation Therapy for MS, Helius Medical PoNS News